Reprogramming the Enemy Within: Patient-Derived CAR-T Cells Effectively Target Inflammation-Inducing B cells

1. Tsokos, G. C. Systemic Lupus Erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).

2. Tabrizi, M., Bornstein, G. G. & Suria, H. Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease. AAPS J. 12, 33–43 (2009).

3. Szöőr, Á. et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484, 1–8 (2020).

4. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).

5. Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715–727 (2021).

6. Zhang, C., Liu, J., Zhong, J. F. & Zhang, X. Engineering CAR-T cells. Biomark. Res. 5, 22 (2017).

7. Dingfelder, J. et al. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production. Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther. 30, 582.e1-582.e10 (2024).